Theodor Billroth performed the first successful gastric resection (a distal subtotal gastrectomy for stomach cancer) in 1881.1 Billroth operated on a 43-yearold woman with gastric outlet obstruction caused by pyloric carcinoma. Despite tolerating the surgical procedure well and having a benign hospital course, the patient died of recurrent gastric cancer 14 months later. Nevertheless, the new s...

Gastric cancer is the third leading cause of cancer-related mortality worldwide. Systemic chemotherapy is the main treatment option for advanced gastric cancer when the tumor is inoperable. Despite recent advances in chemotherapeutic agents, the prognosis of unresectable or recurrent gastric cancer remains extremely poor. In Japan, combination therapy including S-1 and cisplatin is the standard...

background gastric cancer is the second leading cause of cancer-related deaths worldwide and it seems that environmental and lifestyle factors and infection with helicobacter pylori (h. pylori) have a major role in the etiology of gastric cancer. objectives the aim of this study was to investigate the presence of h. pylori dna in archival gastric tissues of patients with gastric cancer disease ...

background the process of neoplastic transformation in the stomach has been reported to be associated with decreased expression of normal mucins of the gastric mucosa and denovo expression of mucins that are normally expressed in other organs. this association may be used as a means to bring new insights into biologic behavior and genetic pathways in the development of gastric cancer. there are...

Gastric cancer and esophageal cancer are the second and sixth leading causes of cancer-related death worldwide. Multiple genomic alterations underlying gastric cancer and esophageal squamous cell carcinoma (ESCC) have been identified, but the full spectrum of genomic structural variations and mutations have yet to be uncovered. Here, we report the results of whole-genome sequencing of 30 sample...

Chemotherapy is of crucial importance in advanced gastric cancer (AGC) patients, in order to obtain palliation of symptoms and improve survival. To date, no standard chemotherapy regimen has been established for AGC. The purpose of the present study was to evaluate the efficacy and toxicity of the combination regimen of paclitaxel and capecitabine (PX) as first-line chemotherapy in patients wit...

BACKGROUND We performed a single-institution retrospective study to evaluate the efficacy and toxicities of combination therapy with docetaxel and S-1 in patients with advanced or recurrent gastric cancer. METHODS Eighty-six patients with advanced or recurrent gastric cancer were enrolled. Patients received docetaxel, 40 mg/m2, on day 1 and oral S-1, 80 mg/m2/day, on days 1 to 14 every 3 week...

PURPOSE We retrospectively determined the efficacy and safety of the combination of oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) as first-line chemotherapy for patients with metastatic or recurrent gastric cancer. MATERIALS AND METHODS Between January 2006 and August 2009, 39 patients with histologically-confirmed, metastatic or recurrent gastric cancer underwent chemotherapy, an...